Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin for neonatal perinatal arterial ischemic stroke
NL-OMON55870Phase 3Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2018
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perinatal arterial ischemic stroke (PAIS) and stroke comparing Darbepoetin with Placebo (2 arms). Primary endpoint: Change in stroke tissue loss. Started Jan 2018; status: recruiting.
02
Drugs
darbepoetin alfa
03
Conditions
perinatal arterial ischemic stroke (PAIS)stroke
Beyond the preview
Go deeper on NL-OMON55870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55870.